药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Trilostane
Encorafenib
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Encorafenib.
Trilostane
Dexverapamil
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dexverapamil.
Trilostane
Levacetylmethadol
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Levacetylmethadol.
Trilostane
Penfluridol
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Penfluridol.
Trilostane
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dexchlorpheniramine.
Trilostane
Lorcainide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Lorcainide.
Trilostane
Bunaftine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Bunaftine.
Trilostane
Nizofenone
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Nizofenone.
Trilostane
Otilonium
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Otilonium.
Trilostane
Sultopride
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Sultopride.
Trilostane
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Sitafloxacin.
Trilostane
Oxatomide
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Oxatomide.
Trilostane
Abexinostat
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Abexinostat.
Trilostane
Mizolastine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mizolastine.
Trilostane
Ricolinostat
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ricolinostat.
Trilostane
Simendan
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Simendan.
Trilostane
CUDC-101
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with CUDC-101.
Trilostane
Gilteritinib
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Gilteritinib.
Trilostane
Entinostat
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Entinostat.
Trilostane
Mocetinostat
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Mocetinostat.